

Epidemiological characteristics of extrapulmonary tuberculosis patients with or without pulmonary tuberculosis

Original Paper

Cite this article: Fang Y, Zhou Q, Li L, Zhou Y, Sha W (2022). Epidemiological characteristics of extrapulmonary tuberculosis patients with or without pulmonary tuberculosis. *Epidemiology and Infection* **150**, e158, 1–5. <https://doi.org/10.1017/S0950268822001236>


Received: 25 January 2022
Revised: 24 April 2022
Accepted: 5 July 2022

Key words:

Co-morbidities; diabetes; epidemiology; extrapulmonary tuberculosis; pulmonary tuberculosis

Author for correspondence:

Wei Sha, Email: 13916239320@163.com

Yong Fang¹, Qinqi Zhou¹, Lin Li¹, Yiming Zhou² and Wei Sha¹ 

¹Clinic and Research Center for Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China and ²Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China

Abstract

Our study aimed to investigate the epidemiology of extrapulmonary tuberculosis (EPTB) and analyse the epidemiological characteristics of EPTB patients with or without pulmonary tuberculosis (PTB). EPTB cases admitted in our hospital from January 2015 to December 2020 were included. Uni- and multi-variable logistic regression analysis was carried out to identify risk factors and prognostic factors of concomitant EPTB and PTB or exclusively EPTB. A total of 3488 EPTB patients were reviewed, including 2086 patients with concurrent PTB and EPTB, and 1402 patients with exclusively EPTB. Logistic regression analysis showed that age >60 years (OR = 1.674, 95% CI = 1.438–1.949, $P < 0.001$) and female (OR = 1.325, 95% CI = 1.155–1.520, $P < 0.001$) were risk factors of exclusively EPTB, while co-morbidities (OR = 0.676, 95% CI = 0.492–0.929, $P = 0.016$) and severe symptoms (OR = 0.613, 95% CI = 0.405–0.929, $P = 0.021$) were risk factors for concurrence of EPTB and PTB. Age >60 years was an independent prognostic factor in EPTB patients with or without PTB (HR = 11.059, 95% CI = 5.097–23.999, $P < 0.001$; HR = 23.994, 95% CI = 3.093–186.151, $P = 0.0020$). Female gender was an independent prognostic factor in patients with concurrent PTB and EPTB (HR = 23.994, 95% CI = 3.093–186.151, $P = 0.002$). Our study disclosed the differential epidemiological characteristics of EPTB patients with or without PTB in China.

Introduction

Tuberculosis (TB) is an infectious disease without widespread effective treatments available caused by *Mycobacterium tuberculosis* and can potentially involve any organ, affecting approximately a quarter of the world's population with more than 10 million new TB cases every year [1]. TB infections affect the lungs in the majority of patients, namely pulmonary tuberculosis (PTB), and also frequently occur in extrapulmonary sites, such as the intestine, meninges, bones, joints and lymph nodes, resulting in extrapulmonary tuberculosis (EPTB) [2, 3]. EPTB can exist alone, or coexist with PTB simultaneously [4]. EPTB has various clinical presentations with head and neck TB as the most common presentation, posing a grave challenge to diagnosis because of its obscure paucibacillary nature and location [5, 6]. Thanks to rapid technological advancements in recent years, the currently used tests for rapid diagnosis have tremendously increased, such as molecular tests GeneXpert assay, liquid culture system (Bactec 960) and line probe assays [7]. Clinical imaging examinations such as ¹⁸F-DG-PET-CT and PET-MRI are critical to determine anatomical localisation and the extent of EPTB [8]. The standard medication for TB or EPTB is a 2-month administration of rifampicin, isoniazid, ethambutol and pyrazinamide followed by a 4-month administration of rifampicin and isoniazid [9].

A recent study reports EPTB in 33.4% of hospitalised TB patients in Beijing Chest Hospital, Beijing, China from January 2008 to December 2017 [10]. Moreover, a large-scale multicentre observation study comprehensively analyses demographic characteristics and prevalence of EPTB in inpatients covering 21 hospitals of 15 provinces in China [11]. However, there is a lack of studies on differential epidemiological characteristics of EPTB patients with or without PTB in China.

An EPTB registration and reporting system has been established in Shanghai, China, since mid-1990s. All newly diagnosed EPTB cases in medical institutions at different levels are reported to TB prevention and control institutes, which regularly conduct random checks on these EPTB cases and further report them to Shanghai Municipal Center for Disease Control. Shanghai Pulmonary Hospital Affiliated to Tongji University School of Medicine is the Shanghai Clinical Research Center for Infectious Diseases (TB), and its newly admitted TB cases account for 60–70% of all TB cases in Shanghai every year. Therefore, it is the most important medical institution for the diagnosis and management of TB in Shanghai. We conducted a retrospective study on all EPTB cases admitted in this hospital from

© The Author(s), 2022. Published by Cambridge University Press. This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided that no alterations are made and the original article is properly cited. The written permission of Cambridge University Press must be obtained prior to any commercial use and/or adaptation of the article.

January 2015 to December 2020, and comparatively analysed epidemiological characteristics of EPTB patients with or without PTB. This study would help reflect epidemiological characteristics of EPTB cases, improve clinical awareness of EPTB and provide helpful guidance on the formulation of treatment regimens.

Methods

Study design

We retrospectively studied all EPTB cases recorded in outpatient and inpatient registers of Shanghai Pulmonary Hospital affiliated to Tongji University School of Medicine from January 2015 to December 2020. The study was approved by the Ethical committee of Shanghai Pulmonary Hospital affiliated to Tongji University School of Medicine. Obtaining written informed consent from each participant preceded this study.

Definitions of TB and diabetes mellitus (DM)

According to previous studies [12, 13], clinical diagnosis of PTB and EPTB was made based on the following terms: 1) typical clinical symptoms of TB such as low-grade fever in the afternoon, night sweats, fatigue and weight loss; 2) positive interferon-gamma release assays (IGRAs) result; 3) positive bacteriological test results of lesion tissue including acid-fast bacilli and positive culture result (Bectec960), or positive GeneXpert test result [14]; 4) typical pathological manifestations including the presence of epithelioid cells, Langhans giant cells and caseous necrosis; 5) supportive imaging findings; 6) systemic and local anti-tuberculosis chemotherapy was effective.

DM [15, 16] was diagnosed based on typical clinical symptoms (polyuria, polydipsia and unexplained weight loss) and random plasma glucose ≥ 11.1 mmol/l or fasting plasma glucose ≥ 7.0 mmol/l (venous whole blood glucose ≥ 6.1 mmol/l) or 2-h plasma glucose ≥ 11.1 mmol/l in oral glucose tolerance test (OGTT). The death indicated all-cause mortality, including any death while still on treatment. Co-morbidities indicated other disorders or illnesses except EPTB or PTB in the same patient, including DM, psychological disorder, pneumoconiosis and others.

Statistical analysis

Statistical analysis was performed using SPSS (IBM, Armonk, New York, version 22.0). Quantitative data were expressed as means \pm standard deviation (s.d.) and compared between different groups using students' *t* test. Qualitative data were expressed as n (%) and compared between different groups using Pearson's chi-square test or Fisher's exact probability test. Significance was defined using $P < 0.05$.

Uni- and multi-variable logistic regression analysis was performed to identify risk factors for concurrent EPTB and PTB, or exclusively EPTB. Uni- and multi-variable cox regression analysis was used to identify significant prognostic factors. Factors with $P < 0.1$ were uni-variately significant and were then entered into multi-variable cox regression analysis.

Results

This study collected a total of 3488 TB patients, including 2086 patients with concurrent PTB and EPTB (EPTB and PTB group, 59.8%), and 1402 patients with exclusively EPTB (EPTB

group, 40.2%). Differences between the EPTB and PTB group and the EPTB group were statistically significant in age (42.82 ± 19.14 years vs. 48.82 ± 19.48 years, $P < 0.001$), gender ($P < 0.001$), incidences of co-morbidities ($P = 0.002$), severe symptoms ($P = 0.015$), whole-course management ($P = 0.007$) and mortality ($P = 0.001$). However, nationality was not significantly different between the two groups ($P = 0.053$, Table 1).

The factors associated with exclusively EPTB were analysed by using uni-variable logistic regression analysis and multi-variable logistic regression analysis. Uni-variable analysis suggested that patients with age >60 years (OR = 1.611; 95% CI = 1.386–1.871, $P < 0.001$) and female gender (OR = 1.285, 95% CI = 1.122–1.472, $P < 0.001$) were positively correlated with exclusively EPTB, whereas severe symptoms were negatively correlated with exclusively EPTB (OR = 0.604, 95% CI = 0.401–0.912, $P = 0.016$, Table 2). No significant correlation was observed for co-morbidities ($P = 0.051$, Table 2). According to multi-variable logistic regression analysis, age >60 years (OR = 1.674, 95% CI = 1.438–1.949, $P < 0.001$) and female gender (OR = 1.325, 95% CI = 1.155–1.520, $P < 0.001$) possessed positive correlations with exclusively EPTB, whereas co-morbidities (OR = 0.676, 95% CI = 0.492–0.929, $P = 0.016$) and severe symptoms (OR = 0.613, 95% CI = 0.405–0.929, $P = 0.021$) possessed negative correlations with exclusively EPTB (Table 2).

During the therapeutic process, 48 (2.3%) and 12 (0.9%) deaths among patients were reported in the EPTB and PTB group and the EPTB group, respectively. Uni-variable Cox regression analysis showed that in the EPTB patients with concurrent PTB, age >60 years (OR = 15.545, 95% CI = 7.276–33.211, $P < 0.001$), co-morbidities (OR = 4.230, 95% CI = 2.107–8.491, $P < 0.001$) and extra-pulmonary involvement ($P = 0.022$) increased the risk of death, while female gender (OR = 0.106, 95% CI = 0.038–0.296, $P < 0.001$) decreased the risk of death (Table 3). Furthermore, according to results of multi-variable Cox regression analysis, age >60 years increased the risk of mortality with a HR value of 11.059 (95%CI = 5.097–23.999, $P < 0.001$, Table 3), while being female decreased the risk of mortality with a HR value of 0.178 (95%CI = 0.063–0.505, $P = 0.001$, Table 3). In contrast, only age was identified to be an independent prognostic factor ($P = 0.002$) for patients with exclusively EPTB by uni- and multi-variable Cox regression analysis, with age >60 years increasing the risk of mortality by 23.994 folds (95%CI = 3.093–186.151, Table 4).

Discussion

Approximately 15–25% of TB infections involve extrapulmonary sites and cause EPTB through haematogenous and lymphatic dissemination of *M. tuberculosis* dissemination [17]. Pleural, lymphatic and musculoskeletal TBs are among the most common sites of EPTB [18]. Clinical signs and symptoms of EPTB vary largely with the affected organ, the disease aggressiveness and the host immune response, and its imaging representations may be vague [19]. According to different EPTB locations and drug resistance, the treatment regimen may need to be adapted, such as elongating treatment time to 9–12 months for CNS and skeletal TB, and addition of steroids for meningeal and pericardial TB [20]. Surgical treatment plays a role in establishing the diagnosis of EPTB and the management of relevant complicated complications [21].

China has the third highest number of TB cases following India and Indonesia, accounting for 8.4% of global TB cases [22]. In the present study, we reviewed 3488 EPTB patients in Shanghai Pulmonary Hospital during the period from January

Table 1. Demographic and clinical characteristics of two groups

Variable	EPTB and PTB group (n = 2086)	EPTB group (n = 1402)	t/ χ^2	P
Age, mean \pm s.d.	42.82 \pm 19.14	48.82 \pm 19.48	-9.021	<0.001
Age, n (%)			39.077	<0.001
\leq 60 years	1591 (76.3)	934 (66.6)		
>60 years	495 (23.7)	468 (33.4)		
Gender, n (%)			13.155	<0.001
Male	1160 (55.6)	692 (49.4)		
Female	926 (44.4)	710 (50.6)		
Nationality, n (%)			3.734	0.053
Han	2086 (100)	1396 (99.7)		
Others	0 (0)	4 (0.3)		
Extra-pulmonary involvement, n (%)			NA	NA
None	0 (0)	1299 (92.7)		
Bones and joints	34 (1.6)	4 (0.3)		
Pleura	228 (10.9)	13 (0.9)		
Meninges	20 (1.0)	3 (0.2)		
Lymph nodes	377 (18.1)	29 (2.1)		
Urinary tract	34 (1.6)	1 (0.1)		
Others	1380 (66.2)	50 (3.6)		
More than one types	13 (0.6)	3 (0.2)		
Co-morbidities, n (%)			15.224	0.002
None	1968 (94.1)	1340 (95.6)		
Psychological disorder	6 (0.3)	7 (0.5)		
Others	26 (1.2)	25 (1.8)		
Diabetes mellitus	92 (4.4)	30 (2.1)		
Severe symptoms n (%)			5.869	0.015
Yes	80 (3.8)	33 (2.4)		
No	2006 (96.2)	1369 (97.6)		
Whole-course management, n (%)			7.158	0.007
Yes	2069 (99.7)	1386 (98.9)		
No	7 (0.3)	15 (1.1)		
Death, n (%)			10.358	0.001
Yes	48 (2.3)	12 (0.9)		
No	2038 (97.7)	1390 (99.1)		

2015 to December 2020. Among them, 2086 patients (59.8%) were diagnosed with both EPTB and PTB, while 1402 patients (40.2%) were diagnosed with EPTB alone. Compared to the patients with exclusively EPTB, the patients with both EPTB and PTB appeared to be significantly younger, had a higher proportion of being male, more likely to suffer from complications or severe symptoms and had a poorer prognosis.

A transversal study conducted in northern Portugal reports that age older than 40 years and female gender are independent risk factors for EPTB [23]. A Turkey study consistently shows that women are more frequently affected by EPTB, while men are more commonly affected by PTB [24]. Yet, younger female patients from rural areas are at a higher risk of EPTB in

Chinese TB patients [10]. It indicates that associations between age and EPTB may vary with geographical and ethnic parameters. Our study found that EPTB alone was prone to occur in female patients older than 60 years, while co-existence of EPTB and PTB was prone to be observed in male patients younger than 60 years, which were in congruence with previous results of a multi-centre observational study in China by Kang *et al.* [11].

EPTB are common in immuno-compromised patients, such as DM patients [25]. DM is a risk factor for TB that strongly impacts the diagnosis and treatment of TB, with the proportion of DM in all TB patients varying from 15% to 25% [2, 26]. Meanwhile TB is a common co-morbidity of depression and may precipitate depression through immune-inflammatory response [27]. EPTB

Table 2. Identification of factors associated with exclusively EPTB by uni- and multi-variable logistic regression analysis

Characteristic	Uni-variate analysis		Multi-variate analysis	
	OR (95% CI)	P	OR (95% CI)	P
Age (>60 vs. ≤60)	1.611 (1.386, 1.871)	<0.001	1.674 (1.438, 1.949)	<0.001
Gender (Female vs. Male)	1.285 (1.122, 1.472)	<0.001	1.325 (1.155, 1.520)	<0.001
Co-morbidities (Yes vs. No)	0.732 (0.536, 1.001)	0.051	0.676 (0.492, 0.929)	0.016
Severe symptoms (Yes vs. No)	0.604 (0.401, 0.912)	0.016	0.613 (0.405, 0.929)	0.021

Table 3. Identification of factors associated with risk of death using uni- and multi-variable Cox regression analysis for patients with concurrent EPTB and PTB

Characteristics	Uni-variate analysis		Multi-variate analysis	
	HR (95% CI)	P-value	HR (95% CI)	P-value
Age (< vs. ≥60)	15.545 (7.276, 33.211)	<0.001	11.059 (5.097, 23.999)	<0.001
Gender (female vs. male)	0.106 (0.038, 0.296)	<0.001	0.178 (0.063, 0.505)	0.001
Co-morbidities (Yes vs. No)	4.230 (2.107, 8.491)	<0.001	1.759 (0.841, 3.680)	0.134
Treatment options (Whole-course management vs. others)	0.152 (0.021, 1.101)	0.062	0.303 (0.041, 2.228)	0.241
Extra- pulmonary involvement		0.022		0.492
Lymph nodes	Reference		Reference	
Pleura	5.526 (1.521, 20.082)	0.009	2.205 (0.595, 8.168)	0.237
Others	2.746 (0.844, 8.927)	0.093	1.754 (0.531, 5.791)	0.356
Severe symptoms (Yes vs. No)	0.419 (0.058, 3.038)	0.389		

Table 4. Identification of factors associated with risk of death using uni- and multi-variable Cox regression analysis for patients with exclusively EPTB

Characteristics	Uni-variate analysis		Multi-variate analysis	
	HR (95% CI)	P-value	HR (95% CI)	P-value
Age (>60 vs. ≤60)	23.551 (3.039, 182.526)	0.002	23.994 (3.093, 186.151)	0.002
Gender (Female vs. Male)	0.325 (0.088, 1.201)	0.092	0.313 (0.085, 1.159)	0.082
Co-morbidities (Yes vs. No)	1.749 (0.226, 13.551)	0.593		
Extra- pulmonary involvement (Yes vs. No)	2.229 (0.488, 10.180)	0.301		

involving central nervous system or causing pericarditis or military tuberculosis can be life-threatening, while osteoarticular and urogenital tuberculosis can be disabling or severely impair functions [28, 29]. In the present study, we found that EPTB patients with concurrent PTB were more likely to suffer from co-morbidities (psychological disorder and DM) and severe symptoms relative to patients with exclusively EPTB. It implies that immune function is weaker in the patients with concurrent EPTB and PTB compared to the patients with exclusively EPTB.

In the present study, 48 patients (2.3%) with concurrent EPTB and PTB and 12 patients (0.9%) with exclusively EPTB died during the therapeutic process. In concordance with a previous study [30], in EPTB patients with or without PTB, age was an independent prognostic factor and increased the risk of mortality by 11.059 fold and 23.994 fold, respectively. Nonetheless, only in the EPTB patients with concurrent PTB, gender was identified to be an independent prognostic factor, and being female decreased the risk of mortality by 82.2%. It implies that male patients with

concurrent EPTB and PTB older than 60 years are prone to have a poor prognosis.

With improved sensitivity and specificity than conventional methods, Xpert MTB/RIF (Xpert) is a fully automated real-time hemi-nested PCR system on the GeneXpert platform that allows for detection of complex DNA of *M. tuberculosis*, and drug susceptibility testing for rifampicin resistance [12]. There is evidence that Gene Xpert is superior to acid-fast bacilli (AFB) smear and culture for the detection of urinary TB using urine specimens [31]. Xpert MTB/RIF is recommended to be an initial diagnostic tool for EPTB [32]. Gene Xpert, Bectec960 culture, and AFB were used for the diagnosis of TB and EPTB in our study.

Some limitations should be noted. Firstly, our study collected data of EPTB cases from one hospital only. Secondly, EPTB cases should be further classified according to extra-pulmonary sites prior to further analysis their clinical characteristics. Thirdly, HIV infection, a common co-morbidity of TB [33], was not focused in the current study. Future studies covering a larger scope of China are warranted to confirm and further our findings concerning Chinese EPTB patients.

Conclusion

Our study summarised epidemiological characteristics of EPTB cases in a hospital in China from January 2015 to December 2020. It showed that 2086 EPTB patients (59.8%) were diagnosed with concomitant PTB. Patients with concomitant TB and EPTB were more likely to be younger males and have high probabilities of comorbidities (psychological disorder and DM) and severe symptoms with a poor outcome. Age >60 years and female gender are risk factors for exclusively EPTB, while co-morbidities and severe symptoms are risk factors for concomitant PTB and EPTB. Female gender is a positive prognostic factor for concomitant TB and EPTB. This study has important implications for surveillance, diagnosis and management of EPTB in China. Concomitant PTB should be screened in EPTB patients to help develop effective treatment regimens.

Data. The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Acknowledgements. None.

Financial support. This work was funded by Shanghai Clinical Research Center for infectious disease (tuberculosis) (Grant ID: 19MC1910800), Shanghai key clinical specialty construction project – Tuberculosis department (Grant ID: Shslczdcz 03001) and Shanghai Leading medical talents Training Program (Grant ID: 2019LJ13).

Conflict of interest. The authors declare that they have no competing interests.

Ethical standards. The study was approved by the Ethnical committee of Shanghai Pulmonary Hospital, School of Medicine, Tongji University. Obtaining written informed consent from each participant preceded this study.

Consent for publication. Not applicable.

Author contributions. Conception and design of the research: Y. F.; acquisition of data: Q. Z. and L. L.; analysis and interpretation of data: Y. F. and Y. Z.; statistical analysis: Y. F. and W. S.; drafting the manuscript: Y. F.; revision of the manuscript for important intellectual content: W. S. All authors read and approved the final manuscript.

References

1. Singh R *et al.* (2020) Recent updates on drug resistance in Mycobacterium tuberculosis. *Journal of Applied Microbiology* **128**, 1547–1567.
2. Ferdous J *et al.* (2019) An overview on epidemiology of Tuberculosis. *Mymensingh Medical Journal* **28**, 259–266.
3. Suárez I *et al.* (2019) The diagnosis and treatment of Tuberculosis. *Deutsches Arzteblatt International* **116**, 729–735.
4. Ohene SA *et al.* (2019) Extra-pulmonary tuberculosis: a retrospective study of patients in Accra, Ghana. *PLoS One* **14**, e0209650.
5. Qian X *et al.* (2019) Head and neck tuberculosis: literature review and meta-analysis. *Tuberculosis (Edinburgh, Scotland)* **116S**, S78–S88.
6. Hayward SE *et al.* (2020) Extrapulmonary tuberculosis among migrants in Europe, 1995 to 2017. *Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases* **27**.
7. Sharma SK, Mohan A and Kohli M (2021) Extrapulmonary tuberculosis. *Expert Review of Respiratory Medicine* **15**, 931–948.
8. Gambhir S *et al.* (2017) Imaging in extrapulmonary tuberculosis. *International Journal of Infectious Diseases: IJID: Official Publication of the International Society for Infectious Diseases* **56**, 237–247.
9. Pascual-Pareja JF *et al.* (2018) Treatment of pulmonary and extrapulmonary tuberculosis. *Enfermedades infecciosas y microbiología clínica (English ed)* **36**, 507–516.
10. Pang Y *et al.* (2019) Epidemiology of extrapulmonary Tuberculosis among inpatients, China, 2008–2017. *Emerging Infectious Diseases* **25**, 457–464.
11. Kang W *et al.* (2020) The epidemiology of extrapulmonary tuberculosis in China: a large-scale multi-center observational study. *PLoS One* **15**, e0237753.
12. Di Tanna GL *et al.* (2019) Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis. *The Lancet Global Health* **7**, e191–e199.
13. Rodriguez-Takeuchi SY, Renjifo ME and Medina FJ (2019) Extrapulmonary Tuberculosis: pathophysiology and imaging findings. *Radiographics: A Review Publication of the Radiological Society of North America, Inc* **39**, 2023–2037.
14. Kohli M *et al.* (2018) Xpert(®) MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. *The Cochrane Database of Systematic Reviews* **8**, Cd012768.
15. Pippitt K, Li M and Gurgle HE (2016) Diabetes Mellitus: screening and diagnosis. *American Family Physician* **93**, 103–109.
16. Kerner W and Brückel J (2014) Definition, classification and diagnosis of diabetes mellitus. Experimental and Clinical Endocrinology & Diabetes: Official Journal. German Society of Endocrinology [and] German Diabetes Association **122**, 384–386.
17. Moule MG and Cirillo JD (2020) Mycobacterium tuberculosis dissemination plays a critical role in pathogenesis. *Frontiers in Cellular and Infection Microbiology* **10**, 65.
18. Leonard MK and Blumberg HM (2017) Musculoskeletal tuberculosis. *Microbiology Spectrum* **5**.
19. Norbis L *et al.* (2014) Challenges and perspectives in the diagnosis of extrapulmonary tuberculosis. *Expert review of Anti-infective Therapy* **12**, 633–647.
20. Natali D *et al.* (2020) What pulmonologists need to know about extrapulmonary tuberculosis. *Breathe* **16**, 200216.
21. Fry DE (2016) Extra-Pulmonary Tuberculosis and Its surgical treatment. *Surgical Infections* **17**, 394–401.
22. Chakaya J *et al.* (2021) Global Tuberculosis report 2020 – reflections on the global TB burden, treatment and prevention efforts. *International Journal of Infectious Diseases*, 1347.e1–1347.e7.
23. Sanches I, Carvalho A and Duarte R (2015) Who are the patients with extrapulmonary tuberculosis? *Revista portuguesa de pneumologia* **21**, 90–93.
24. Sunnetcioglu A *et al.* (2015) Comparative analysis of pulmonary and extrapulmonary tuberculosis of 411 cases. *Annals of Clinical Microbiology and Antimicrobials* **14**, 34.
25. Gaifer Z (2017) Epidemiology of extrapulmonary and disseminated tuberculosis in a tertiary care center in Oman. *International Journal of Mycobacteriology* **6**, 162–166.
26. Jacob S *et al.* (2020) Prevalence of diabetes mellitus and HIV/AIDS among tuberculosis patients in Kerala. *Journal of Family Medicine and Primary Care* **9**, 6209–6212.
27. Zhang K *et al.* (2019) The interplay between depression and tuberculosis. *Journal of Leukocyte Biology* **106**, 749–757.
28. Figueiredo AA, Lucon AM and Srougi M (2017) Urogenital tuberculosis. *Microbiology Spectrum* **5**.
29. Vohra S and Dhaliwal HS (2021) Miliary Tuberculosis. In *StatPearls*. Treasure Island, FL: StatPearls Publishing. Copyright © 2021, StatPearls Publishing LLC.
30. Uchida S *et al.* (2019) A mini systematic review of prognostic factors in elderly patients with tuberculosis. *Respiratory Investigation* **57**, 207–212.
31. Pang Y *et al.* (2017) GeneXpert MTB/RIF assay in the diagnosis of urinary tuberculosis from urine specimens. *Scientific Reports* **7**, 6181.
32. Tadesse M *et al.* (2019) Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a diagnostic evaluation study. *Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases* **25**, 1000–1005.
33. Letang E *et al.* (2020) Tuberculosis-HIV Co-infection: progress and challenges after Two decades of global antiretroviral treatment roll-Out. *Archivos de bronconeumologia* **56**, 446–454.